HDAC4-IN-1_product_DataBase

Bioactivity	HDAC4-IN-1 (compound 1a) is a class IIa HDACI inhibitor (IC50=0.077 μM). HDAC4-IN-1 can enhance Caspase-induced Apoptosis. HDAC4-IN-1 has anticancer activity. HDAC4-IN-1 can be used in the research of drug combination against cancer[1].
Invitro	HDAC4-IN-1 能够显著抑制 IIa 类 HDAC (IC50=0.077 μM) [1]。HDAC4-IN-1 (100 μM; 72 h) 在 THP-1 细胞中的细胞毒性很低 (IC50=9.2 μM) 但与 BTZ 结合后，具有很强的协同作用，增强了 BTZ 对细胞的细胞毒作用[1]。HDAC4-IN-1 (5 μM; 48 h) 与 BTZ (7.9 nM) 联合使用可以诱导 caspase 介导的细胞凋亡[1]。HDAC4-IN-1 (5 μM; 24 h) 与 BTZ (7.9 nM) 联合使用在 THP-1 细胞能够增强 p21 蛋白的表达[1]。HDAC4-IN-1 (5 μM; 72 h) 在癌细胞系 Cal27_HDAC4 中能够抑制细胞增殖[1]。 0 --> HDAC4-IN-1 相关抗体: Cell Viability Assay[1] Cell Line:
Name	HDAC4-IN-1
CAS	1418293-39-6
Formula	C16H19F3N4O2
Molar Mass	356.34
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Asfaha Y, et al. 5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib. Eur J Med Chem. 2023 Nov 10;263:115907.

PeptideDB